Cefetamet pivoxil in otitis media.

Abstract

In this multicentre, open, randomized, parallel-group study, 270 children with acute otitis media aged between 1 and 15 years were randomized to receive either cefetamet pivoxil 10 mg/kg b.i.d. for 7 days (n = 134) or cefaclor 13.5 mg/kg t.i.d. for 7 days (n = 136). At the end of treatment, bacteriological cure occurred in 44/44 (100%) patients receiving cefetamet pivoxil and 24/28 (86%) patients receiving cefaclor. Clinical cure or improvement was experienced by 117/121 (97%) of patients receiving cefetamet pivoxil and 104/115 (90%) patients in the cefaclor group. Adverse side effects, mainly gastrointestinal disorders, occurred in 11% of patients in the cefetamet pivoxil group compared with 15% of patients in the cefaclor group. All adverse events were of mild or moderate severity and subsided rapidly after treatment. Premature treatment withdrawals occurred in 0.7% of patients who received cefetamet pivoxil and in 2.2% of those who received cefaclor.

• Authors: A Quevedo, R Sossouhounto, M Kissling
• Journal: ORL; journal for oto-rhino-laryngology and its related specialties (ORL J Otorhinolaryngol Relat Spec) 1993 Mar-Apr Vol. 55 Issue 2 Pg. 93-6 ISSN: 0301-1569 [Print] Switzerland
• PMID: 8446394 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Cefaclor
• Ceftizoxime
• cefetamet pivoxyl

Topics

• Acute Disease
• Administration, Oral
• Adolescent
• Cefaclor (administration & dosage, therapeutic use)
• Ceftizoxime (administration & dosage, analogs & derivatives, therapeutic use)
• Child
• Child, Preschool
• Drug Tolerance
• Follow-Up Studies
• Haemophilus Infections (drug therapy)
• Haemophilus influenzae (drug effects)
• Humans
• Infant
• Otitis Media (drug therapy, microbiology)
• Pneumococcal Infections (drug therapy)
• Remission Induction
• Streptococcal Infections (drug therapy)
• Streptococcus pyogenes (drug effects)